Daily Briefing – May 14: Omeros launch numbers, Aquestive resubmission path, Intuitive Machines earnings and biotech PDUFA setups drive the tape

The May 14 setup is more event-driven than thematic. Biotech remains active after Omeros reported first-quarter results showing YARTEMLEA gross product sales of $11.1 million and net sales of $9.9 million in its first commercial quarter, while Aquestive reaffirmed plans to resubmit the Anaphylm NDA in Q3 2026 after completing its FDA Type A meeting and confirming that the January CRL did not identify CMC deficiencies. INOVIO added another late-2026 regulatory watch after reporting that INO-3107 remains under active FDA review with an October 30, 2026 PDUFA date and cash expected to fund operations into Q1 2027. Capricor remains one of the most visible FDA-calendar names with deramiocel under active BLA review and an August 22, 2026 PDUFA date. In space and defense, Intuitive Machines is the key live earnings name today, with Q1 2026 results scheduled before the market open and investors focused on revenue conversion, backlog quality and the company’s broader 2026 execution plan. Rocket Lab, Redwire, BlackSky, Kratos and Red Cat remain in rotation after recent Q1 updates, while cannabis stays policy-sensitive ahead of the DEA marijuana rescheduling hearing scheduled to begin June 29, 2026 and conclude no later than July 15, 2026.

Main single-stock stories
  • OMER— Omeros reported Q1 results with YARTEMLEA gross product sales of $11.1 million and net sales of $9.9 million, putting the first commercial launch quarter at the center of the watch caseEarnings
  • AQST— Aquestive reaffirmed guidance to resubmit the Anaphylm NDA in Q3 2026 after FDA Type A meeting alignment, with no CMC deficiencies cited in the prior CRLFDA
  • LUNR— Intuitive Machines is the main space-earnings event today, with Q1 results due before the market open and investors watching revenue, backlog and 2026 executionSpace
  • INO— INOVIO reported that INO-3107 remains under active FDA review with an October 30, 2026 PDUFA date and cash expected to fund operations into Q1 2027PDUFA
  • CAPR— Capricor remains a key FDA-calendar watch after confirming deramiocel is under active BLA review with an August 22, 2026 PDUFA datePDUFA
  • CING— Cingulate stays on the near-term catalyst list with the May 31, 2026 PDUFA date for CTx-1301 keeping ADHD regulatory risk in focusPDUFA
  • RKLB— Rocket Lab remains the space-basket leader after record Q1 revenue of $200.3 million, record backlog of $2.2 billion and Q2 guidance of $225 million-$240 millionSpace
  • RDW— Redwire remains active after Q1 revenue of $97.0 million, up 57.9% year over year, with the market watching margin progress and Edge Autonomy integrationSpace Defense
  • BKSY— BlackSky continues to support the space-AI lane after Q1 revenue of $20.8 million and raised 2026 revenue guidance to $130 million-$150 millionSpace AI
  • SOUN— SoundHound AI remains in the small-cap AI rotation after Q1 revenue of $44.2 million, with traders still judging growth quality, losses and cash disciplineAI
Macro & tape pressure
  • PDUFA calendar is building— CAPR, INO, CING, ZYME and UNCY keep FDA timing at the center of the biotech tape as traders move closer to late-May and summer decision windowsFDA
  • Commercial biotech is back in focus— OMER’s first YARTEMLEA quarter shifts attention from pure regulatory optionality to actual launch uptake, net sales and cash-flow timingBiotech
  • CRL recovery stories need precision— AQST remains a cleaner example because the company says the Anaphylm CRL did not identify CMC deficiencies, but resubmission timing still depends on completing the required studiesFDA Risk
  • Space earnings are execution tests— LUNR, RKLB, RDW and BKSY are being judged on contract conversion, funded backlog, gross margin, cash burn and whether guidance can survive real delivery timelinesSpace
  • Defense backlog remains important— KTOS, RCAT, ONDS, AVAV and BBAI stay tied to procurement visibility, battlefield relevance, funded awards and whether orders turn into profitable revenueDefense
  • AI is still selective— SOUN, BBAI, CXAI and related software names need more than headline revenue growth: the market is watching organic growth, losses, acquisition integration and balance sheetsAI
  • Cannabis policy remains live— The DEA marijuana rescheduling hearing is scheduled to begin June 29, 2026, keeping TLRY, CGC, CRON, MSOS and IIPR on watchCannabis
Themes & rotation
  • Biotech catalyst trading remains active— CAPR, INO, AQST, CING, UNCY, ZYME, OMER and CMPS give traders a mix of PDUFA dates, resubmission paths, earnings calls, launch metrics and balance-sheet questionsBiotech
  • FDA clarity beats vague momentum— The strongest biotech setups are those where investors can map the next event: PDUFA date, BLA/NDA resubmission, mid-cycle review, advisory risk or commercial launch metricFDA
  • Space-defense still leads high beta— LUNR, RKLB, RDW, BKSY, PL and HAWK keep the public-market space theme focused on lunar infrastructure, launch, satellite intelligence and defense demandSpace
  • Drones remain a core defense lane— Red Cat, Kratos, Ondas and AeroVironment keep the rotation focused on unmanned systems, tactical procurement, battlefield technology and production scaleDrones
  • Backlog quality matters— The strongest space and defense stories now need funded work, revenue conversion, margin improvement and cash discipline, not just big headline awardsQuality
  • Small-cap AI is under a stricter filter— SOUN, BBAI, CXAI and related names remain active, but investors are judging organic growth, losses, integration risk and whether demand is recurringAI
Tickers to monitor
  • OMER / AQST / INO / CAPR / CING / UNCY— Biotech names with active launch updates, FDA review paths, PDUFA dates, resubmission timing or near-term regulatory relevance remain central to the May watchlistBiotech
  • CMPS / MLTX / ZYME / AVTX / STOK / XBI— Small and mid-cap biotech stays active across earnings, BLA planning, clinical data, financing risk and sector betaBiotech Risk
  • LUNR / RKLB / RDW / BKSY / HAWK / GSAT / PL— The space basket remains active, with focus on lunar missions, launch contracts, satellite intelligence, defense demand and cash runwaySpace
  • RCAT / KTOS / ONDS / AVAV / DRS / RTX— Defense and drone names stay in focus as traders compare revenue scale, battlefield relevance, funded orders, margins and procurement visibilityDefense Drones
  • SOUN / BBAI / CXAI / AI / PDYN / PATH— Small-cap and software AI should be watched through a stricter lens: real revenue, organic growth, integrations, backlog quality and cash runwayAI
  • NVDA / AMD / ARM / AVGO / MU / AMAT— Semis remain central to the broader tape as traders watch data-center demand, AI capex, China/trade headlines, valuation and earnings reactionsSemis
  • TLRY / CGC / CRON / MSOS / IIPR— Cannabis names remain policy-sensitive ahead of the June 29 DEA hearing tied to the broader marijuana rescheduling processCannabis
Tape watch
  • Omeros launch read-through— OMER’s Q1 report gives investors an early commercial signal for YARTEMLEA, but the real debate now shifts to durability of uptake, expenses and cash-flow timingLaunch
  • Aquestive resubmission path— AQST remains a Q3 2026 resubmission story for Anaphylm, with the required human factors and PK work now the key bridge after FDA Type A meeting alignmentFDA
  • Intuitive Machines earnings test— LUNR’s Q1 print is the live space event today, with the market likely to focus on revenue ramp, backlog conversion and credibility of the broader 2026 outlookEarnings
  • INOVIO PDUFA watch— INO now sits on an October 30, 2026 FDA action date for INO-3107, with accelerated-approval eligibility, commercial readiness and cash runway all part of the risk/reward mapPDUFA
  • Capricor review window— CAPR’s August 22, 2026 PDUFA date for deramiocel remains one of the cleaner summer biotech catalyst dates, with manufacturing readiness and labeling still important to watchPDUFA
  • Cingulate late-May risk— CING’s May 31 PDUFA date is close enough to keep trading interest high, but micro-cap biotech risk, financing and label/commercial questions still matterBiotech Risk
  • Rocket Lab leadership check— RKLB still has the strongest space tape, but the next question is whether backlog growth, launch cadence and Neutron expectations support continued follow-throughSpace
  • PDUFA and policy calendar— CING’s May 31 date, UNCY’s June 29 PDUFA, CAPR’s August 22 date, ZYME’s August 25 zanidatamab date and the June 29 DEA hearing all belong on the catalyst calendarCatalysts
Read the full Daily Briefing
Free Course

Run-Up Biotech Masterclass

Learn how to read biotech catalysts, trial results and FDA decisions with a practical framework.

Open
Educational only.
 Tracking Tool

Biotech Catalyst Calendar

Track FDA events, clinical readouts and biotech catalysts with a practical event-driven tool.

Open Archive

Browse the Blog & Archive

Explore articles, biotech deep dives, market notes, reports and archived sector content.

Open Reality Check

Biotech Trading Without the Fairy Tales

A grounded piece on risk, catalysts, dilution, volatility and biotech trading reality.

Open 2026 Watchlist

The New Era – Space, Defense & AI

A thematic watchlist built around military spending, strategic technology and AI-linked trends.

Open Briefing

SPACE AI DEFENCE

A thematic briefing at the intersection of defense, space infrastructure and AI.

Open Top List

Top 10 Defense-Tech Stocks to Watch

A focused list built around defense technology, drones and strategic systems.

Open Top List

Top 5 U.S. Airlines Watchlist

A practical watchlist for pricing power, fuel sensitivity, travel demand and macro tone.

Open Top List

Top 5 Cruise Lines Watchlist

A leisure-focused list centered on major cruise operators and pricing-driven sentiment.

Open
Scanner for active traders

Try ChartsWatcher free, then unlock 10% OFF with SAVE10

ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and sector rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.

Start with the free version. When you upgrade, use SAVE10 to get 10% OFF your first paid period.

Start free – then use SAVE10

No credit card required to start. Apply SAVE10 when upgrading.

ChartsWatcher platform screenshot
Recommended platform

One platform. All your brokers.

Medved Trader connects multiple brokers in one workspace, with professional charts, hotkeys and fast execution — without changing your broker accounts.

A single cockpit for positions, Level II and multi-broker order routing, built for active day and swing traders.

Get 1 Month Free ➔

Multi-broker workflow + customizable layouts in one platform.

Medved Trader platform dashboard
Monica.im Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site

Find out how I use AI on Merlintrader: AI, retail and Merlintrader

Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.

Merlintrader author

Authors: Merlintrader, Jane and Gemini

Author’s note

In every report I share what I see and how I personally interpret it, based on raw data from official company filings, regulatory documents, conference call transcripts and other primary sources where available. Some parts of the research and structure are supported by AI assistants, which help me organize the data, re-check details and improve charts or visual elements. However, any interpretation, opinion and final judgment remain entirely mine, as a trader and not as a licensed financial advisor or registered analyst. Market sentiment can change quickly, while official documents and numbers remain what they are. It is also possible for me to make mistakes: collecting and cross-checking FDA timelines, clinical data, filings and corporate updates is a complex job, so inaccuracies may occur. If you notice something that seems off, feel free to tell me and I will correct it. Please do not treat this report as professional investment advice, but as one more source of information to compare with your own research and with the opinion of qualified professionals.

AI usage disclosure

This report has been prepared using a human + AI workflow. Drafting, editing and data organization are supported by generative AI tools, such as large language models provided by third parties, based on prompts and instructions defined by the author. All sources used are public, and the final selection of data, checks, opinions and conclusions remains with the author, who takes full responsibility for the content.

If you find these reports useful and want to support the project, you can make a voluntary one-time donation via PayPal or Buy Me a Coffee. It helps cover data, tools and hosting costs, so the content can remain independent and freely accessible.

Buy Me a Coffee

Biotech Catalyst Calendar

For a broader and continuously updated view of upcoming biotech catalysts — PDUFA dates, major clinical readouts, regulatory events and key conferences — you can visit the dedicated calendar on Merlintrader.

Open the Biotech Catalyst Calendar